The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world's most advanced psychedelic pharmaceutical grade manufacturers, thereby ...

The gross proceeds to the Company from the offering were approximately $5.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends ...

Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET ...

A live and archived webcast of the event will also be available on the “Investor Relations” section of the Heartflow website at The archived version will be available for 12 months following ...

This notice has no immediate effect on the listing of the Company’s ADSs, which will continue to trade at this time on the Nasdaq Global Select Market under the symbol “TRIB.” In accordance with ...

NORTH PALM BEACH, Fla., Feb. 13, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company” or " SRXH " ), a pet health and wellness company, today announced its ...

Bitopertin is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide. Disc obtained global rights to bitopertin under a license agreement from Roche in May ...

Upon detecting the unusual activity, Inotiv promptly took steps to contain it and launched an investigation with the support of external cybersecurity specialists. Inotiv also notified regulators and ...

Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.6 million, or ...

(NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced ...

With Paretofit, a coaching system built around the 80/20 principle, entrepreneurs and self-employed professionals can now access a structured digital program that translates interdisciplinary, science ...

For the quarter ended December 31, 2025, Edesa reported a net loss of $2.2 million, or $0.28 per common share, compared to a net loss of $1.6 million, or $0.48 per common share, for the quarter ended ...